Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications

References

• Charlie H, Uludaǧ H. Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression. J Drug Target. 2012;20(4):301–328.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA. Nucleic acid nanoparticles at a crossroads of vaccines and immunotherapies. Molecules. 2019;24:4620.
   PubMed Web of Science ®Google Scholar
• Viola JR, Rafael DF, Wagner E, et al. Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. J Drug Deliv. 2013;2013:1–15.
   Google Scholar
• Weng Y, Huang Q, Li C, et al. Improved nucleic acid therapy with advanced nanoscale biotechnology. Mol Ther Nucleic Acids. 2020;19:581–601.
   PubMedGoogle Scholar
• Sridharan K, Gogtay NJ. Therapeutic nucleic acids: current clinical status. Br J Clin Pharmacol. 2016;82(3):659–672.
   PubMed Web of Science ®Google Scholar
• Xiong H, Diermeier SD. Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sci. 2021;22:3295.
   PubMed Web of Science ®Google Scholar
• Gupta A, Andresen JL, Manan RS, et al. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021;178:113834.
   PubMed Web of Science ®Google Scholar
• Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013;25:152–159.
   PubMed Web of Science ®Google Scholar
• Maruggi G, Zhang C, Li J, et al. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019;27:757–772.
   PubMed Web of Science ®Google Scholar
• Iavarone C, O’hagan DT, Yu D, et al. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017;16(9):871–881.
   PubMed Web of Science ®Google Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–1973.
   PubMed Web of Science ®Google Scholar
• Baum C, Kustikova O, Modlich U, et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17(3):253–263.
   PubMed Web of Science ®Google Scholar
• Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11:10–17.
   PubMed Web of Science ®Google Scholar
• Bouard D, Alazard-Dany N, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol. 2009;157:153–165.
   PubMed Web of Science ®Google Scholar
• Ickenstein LM, Garidel P. Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin Drug Deliv. 2019;16:1205–1226.
   PubMed Web of Science ®Google Scholar
• Evers MJW, Kulkarni JA, van der Meel R, et al. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small. 2018;2:1700375.
   Web of Science ®Google Scholar
• Maeki M, Uno S, Niwa A, et al. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release. 2022;344:80–96.
   PubMed Web of Science ®Google Scholar
• Ramamoorth M, Narvekar A. Nonviral vectors in gene therapy - An overview. J Clin Diagn Res. 2015;9:1–6.
   Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346–358.
   PubMed Web of Science ®Google Scholar
• Jafari M, Soltani M, Naahidi S, et al. Nonviral approach for targeted nucleic acid delivery. Curr Med Chem. 2012;19:197–208.
   PubMed Web of Science ®Google Scholar
• Pathak K, Keshri L, Shah M. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics. Crit Rev Ther Drug Carrier Syst. 2011;28:357–393.
   PubMed Web of Science ®Google Scholar
• Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–2387.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4:e10143.
   PubMed Web of Science ®Google Scholar
• Bisso S, Leroux JC. Nanopharmaceuticals: a focus on their clinical translatability. Int J Pharm. 2020;578:119098.
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–999.
   PubMed Web of Science ®Google Scholar
• Çağdaş M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. Appl nanotechnol drug del. 2014;1:1–50.
   Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4:297–305.
   PubMedGoogle Scholar
• Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272.
   PubMed Web of Science ®Google Scholar
• Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev. 2012;64:1730–1737.
   PubMed Web of Science ®Google Scholar
• Desfrançois C, Auzély R, Texier I. Lipid nanoparticles and their hydrogel composites for drug delivery: a review. Pharmaceuticals. 2018;11:118.
   Web of Science ®Google Scholar
• Manjunath K, Ready JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol. 2005;27:127–144.
   PubMed Web of Science ®Google Scholar
• Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001;46:169–185.
   PubMed Web of Science ®Google Scholar
• Kim CH, Lee SG, Kang MJ, et al. Surface modification of lipid-based nanocarriers for cancer cell-specific drug targeting. J Pharm Invest. 2017;47:203–227.
   Google Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62:90–99.
   PubMed Web of Science ®Google Scholar
• Attia MF, Anton N, Wallyn J, et al. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71:1185–1198.
   PubMed Web of Science ®Google Scholar
• Richards DA, Maruani A, Chudasama V. Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem Sci. 2017;8:63–77.
   PubMed Web of Science ®Google Scholar
• Wu L, Tang C, Yin C. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm. 2010;36:439–448.
   PubMed Web of Science ®Google Scholar
• Zhang S, Lu C, Zhang X, et al. Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system. Drug Deliv. 2016;23:1838–1845.
   PubMed Web of Science ®Google Scholar
• Ucar E, Teksoz S, Ichedef C, et al. Synthesis, characterization and radiolabeling of folic acid modified nanostructured lipid carriers as a contrast agent and drug delivery system. Appl Radiat Isot. 2017;119:72–79.
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127–1141.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Tyagi P, Li S, et al. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer. 2004;112:693–700.
   PubMed Web of Science ®Google Scholar
• Shan D, Li J, Cai P, et al. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 2015;5:15–26.
   PubMed Web of Science ®Google Scholar
• Song S, Mao G, Du J, et al. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv. 2016;23:1404–1408.
   PubMed Web of Science ®Google Scholar
• Su Z, Niu J, Xiao Y, et al. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm. 2011;8:1641–1651.
   PubMed Web of Science ®Google Scholar
• Su Z, Shi Y, Xiao Y, et al. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization. Int J Pharm. 2013;447:281–292.
   PubMed Web of Science ®Google Scholar
• Taratula O, Kuzmov A, Shah M, et al. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release. 2013;171:349–357.
   PubMed Web of Science ®Google Scholar
• Du J, Li L. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers? Drug Deliv. 2016;23:1799–1809.
   PubMed Web of Science ®Google Scholar
• Liu B, Han L, Liu J, et al. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine. 2017;12:955–968.
   PubMed Web of Science ®Google Scholar
• Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett. 2013;334:221–227.
   PubMed Web of Science ®Google Scholar
• Mohammadi Ghalaei P, Varshosaz J, Sadeghi Aliabadi H. Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 cells. J Drug Deliv. 2014;2014:1–7.
   Google Scholar
• Tran TH, Choi JY, Ramasamy T, et al. Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polym. 2014;114:407–415.
   PubMed Web of Science ®Google Scholar
• Qu CY, Zhou M, Chen YW, et al. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int J Nanomedicine. 2015;10:3911–3920.
   PubMed Web of Science ®Google Scholar
• Shen H, Shi S, Zhang Z, et al. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics. 2015;5:755–771.
   PubMed Web of Science ®Google Scholar
• Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148:359–367.
   PubMed Web of Science ®Google Scholar
• Jain A, Kesharwani P, Garg NK, et al. Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. Colloids Surf B Biointerfaces. 2015;134:47–58.
   PubMed Web of Science ®Google Scholar
• van der Jeught K, de Koker S, Bialkowski L, et al. Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety. ACS Nano. 2018;12:9815–9829.
   PubMed Web of Science ®Google Scholar
• Khajavinia A, Varshosaz J, Dehkordi AJ. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology. 2012;23:405101.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang Y, Li D, et al. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine. 2014;9:4107–4116.
   PubMed Web of Science ®Google Scholar
• Shao Z, Shao J, Tan B, et al. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine. 2015;10:1223–1233.
   PubMed Web of Science ®Google Scholar
• Layek B, Lipp L, Singh J. Cell penetrating peptide conjugated chitosan for enhanced delivery of nucleic acid. Int J Mol Sci. 2015;16:28912–28930.
   PubMed Web of Science ®Google Scholar
• Asai T, Tsuzuku T, Takahashi S, et al. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. Biochem Biophys Res Commun. 2014;444:599–604.
   PubMed Web of Science ®Google Scholar
• Li Y, Lee RJ, Yu K, et al. Delivery of siRNA using lipid nanoparticles modified with cell penetrating peptide. ACS Appl Mater Interfaces. 2016;8:26613–26621.
   PubMed Web of Science ®Google Scholar
• Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials. 2010;31:6867–6875.
   PubMed Web of Science ®Google Scholar
• Rizwan SB, McBurney WT, Young K, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165:16–21.
   PubMed Web of Science ®Google Scholar
• Roces CB, Lou G, Jain N, et al. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics. 2020;12:1095.
   PubMed Web of Science ®Google Scholar
• Berger N, Sachse A, Bender J, et al. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm. 2001;223:55–68.
   PubMed Web of Science ®Google Scholar
• Comuzzo P, Calligaris S. Potential applications of high pressure homogenization in winemaking: a review. Beverages. 2019;5:56.
   Web of Science ®Google Scholar
• International Organization for Standardization. 2022. ISO 10991:2009 micro process engineering — Vocabulary. https://www.iso.org/standard/46546.html. [Accessed 2022 Jun 15]
   Google Scholar
• Khan IU, Serra CA, Anton N, et al. Production of nanoparticle drug delivery systems with microfluidics tools. Expert Opin Drug Deliv. 2015;12:547–562.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay R. When PDMS isn’t the best. Anal Chem. 2007;79:3248–3253.
   PubMedGoogle Scholar
• Karnik R, Gu F, Basto P, et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 2008;8:2906–2912.
   PubMed Web of Science ®Google Scholar
• Nisisako T, Torii T. Microfluidic large-scale integration on a chip for mass production of monodisperse droplets and particles. Lab Chip. 2008;8:287–293.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay R. When microfluidic devices go bad. Anal Chem. 2005;77:429–432.
   Web of Science ®Google Scholar
• Silverio V, S C. Lab-on-a-chip: systems integration at the microscale. Drug Delivery Devices Therapeutic Systems. 2021;4:63–87.
   Google Scholar
• Mansur EA, Ye M, Wang Y, et al. A state-of-the-art review of mixing in microfluidic mixers. Chin J Chem Eng. 2008;16:503–516.
   Web of Science ®Google Scholar
• Maeki M, Fujishima Y, Sato Y, et al. Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers. PLOS ONE. 2017;12:e187962.
   PubMed Web of Science ®Google Scholar
• de Menech M, Garstecki P, Jousse F, et al. Transition from squeezing to dripping in a microfluidic T-shaped junction. J Fluid Mech. 2008;595:141–161.
   Web of Science ®Google Scholar
• Prakash S, Kumar S 2015. Fabrication of microchannels: a review. Proceedings of the Institution of Mechanical Engineers, Part B: Journal of Engineering Manufacture San Diego (CA), USA. 229:1–16.
   Google Scholar
• Krzysztoń R, Salem B, Lee DJ, et al. Microfluidic self-assembly of folate-targeted monomolecular siRNA-lipid nanoparticles. Nanoscale. 2017;9:7442–7453.
   PubMed Web of Science ®Google Scholar
• Kimura N, Maeki M, Sato Y, et al. Development of the iLiNP device: fine tuning the lipid nanoparticle size within 10 nm for drug delivery. ACS Omega. 2018;3:5044–5051.
   PubMed Web of Science ®Google Scholar
• Webb C, Forbes N, Roces CB, et al. Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes. Int J Pharm. 2020;582:119266.
   PubMed Web of Science ®Google Scholar
• Belliveau NM, Huft J, Lin PJ, et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids. 2012;1:e37.
   PubMedGoogle Scholar
• Arteta MY, Kjellman T, Bartesaghi S, et al. 2018. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proceedings of the National Academy of Sciences. 115:3351–3360.
   Google Scholar
• Chen S, Tam YYC, Lin PJC, et al. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J Control Release. 2016;235:236–244.
   PubMed Web of Science ®Google Scholar
• Liang F, Lindgren G, Lin A, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25:2635–2647.
   PubMed Web of Science ®Google Scholar
• VanBlargan LA, Himansu S, Foreman BM, et al. An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections. Cell Rep. 2018;25:3382–3392.
   PubMed Web of Science ®Google Scholar
• Zeng C, Hou X, Yan J, et al. Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo. bioRxiv. 2020;32:e2004452.
   Google Scholar
• Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–1555.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against zika virus infection. Cell. 2017;168:1114–1125.
   PubMed Web of Science ®Google Scholar
• Awasthi S, Hook LM, Pardi N, et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol. 2019;4(39):eaaw7083.
   PubMed Web of Science ®Google Scholar
• John S, Yuzhakov O, Woods A, et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36(12):1689–1699.
   PubMed Web of Science ®Google Scholar
• Roth C, Cantaert T, Colas C, et al. A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice. Front Immunol. 2019;10:1424.
   PubMed Web of Science ®Google Scholar
• Meyer M, Huang E, Yuzhakov O, et al. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J Infect Dis. 2018;217(3):451–455.
   PubMed Web of Science ®Google Scholar
• Miao L, Li L, Huang Y, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37(10):1174–1185.
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Tonnu N, Tachikawa K, et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Nat Acad Sci. 2017;114(10):1941–1950.
   PubMed Web of Science ®Google Scholar
• Jiang L, Berraondo P, Jericó D, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018;24(12):1899–1909.
   PubMed Web of Science ®Google Scholar
• Zhang C, Maruggi G, Shan H, et al. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.
   PubMed Web of Science ®Google Scholar
• Tiwari PM, Vanover D, Lindsay KE, et al. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun. 2018;9:3999.
   PubMed Web of Science ®Google Scholar
• Manara C, Brazzoli M, Piccioli D, et al. Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines. Vaccine. 2019;37:4204–4213.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25:1316–1327.
   PubMed Web of Science ®Google Scholar
• Lindgren G, Ols S, Liang F, et al. Induction of Robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol. 2017;8:1539.
   PubMed Web of Science ®Google Scholar
• Hassett KJ, Benenato KE, Jacquinet E, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids. 2019;15:1–11.
   PubMedGoogle Scholar
• Thran M, Mukherjee J, Pönisch M, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9(10):1434–1447
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248–251.
   PubMed Web of Science ®Google Scholar
• Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630.
   PubMed Web of Science ®Google Scholar
• Kose N, Fox JM, Sapparapu G, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol. 2019;4:eaaw6647.
   PubMed Web of Science ®Google Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, et al. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017;17(3):1326–1335.
   PubMed Web of Science ®Google Scholar
• Lee K, Kim SY, Seo Y, et al. Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy. Biomater Sci. 2020;8(4):1101–1105.
   PubMed Web of Science ®Google Scholar
• Nabhan JF, Wood KM, Rao VP, et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia. Sci Rep. 2016;6(1):20019.
   PubMedGoogle Scholar
• Robinson E, MacDonald KD, Slaughter K, et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol Ther. 2018;26(8):2034–2046.
   PubMed Web of Science ®Google Scholar
• Dumpa N, Goel K, Guo Y, et al. Stability of Vaccines. AAPS PharmSciTech. 2019;20(2):42.
   PubMed Web of Science ®Google Scholar
• Chen C, Yang Z, Tang X. Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. Med Res Rev. 2018;38(3):829–869.
   PubMed Web of Science ®Google Scholar
• Howard MD, Lu X, Jay M, et al. Optimization of the lyophilization process for long-term stability of solid–lipid nanoparticles. Drug Dev Ind Pharm. 2012;38(10):1270–1279.
   PubMed Web of Science ®Google Scholar
• Fonte P, Andrade F, Azevedo C, et al. Effect of the freezing step in the stability and bioactivity of protein-loaded PLGA nanoparticles upon lyophilization. Pharm Res. 2016;33(11):2777–2793.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur J Pharm Biopharm. 2006;63(2):87–94.
   PubMed Web of Science ®Google Scholar
• Jones KL, Drane D, Gowans EJ. Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques. 2007;43(5):675–681.
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30(12):1210–1216.
   PubMed Web of Science ®Google Scholar
• Stitz L, Vogel A, Schnee M, et al. A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis. 2017;11(12):e0006108.
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–1520.
   PubMed Web of Science ®Google Scholar
• Zhao P, Hou X, Yan J, et al. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact Mater. 2020;5(2):358–363.
   PubMed Web of Science ®Google Scholar
• Yusuf H, Kett V. Current prospects and future challenges for nasal vaccine delivery. Hum Vaccines Immunother. 2017;13(1):34–45.
   PubMed Web of Science ®Google Scholar
• Tonnis WF, Kersten GF, Frijlink HW, et al. Pulmonary vaccine delivery: a realistic approach? J Aerosol Med Pulm Drug Deliv. 2012;25(5):249–260.
   PubMed Web of Science ®Google Scholar
• Chablani L, Tawde SA, D’Souza MJ. Spray-dried microparticles: a potential vehicle for oral delivery of vaccines. J Microencapsul. 2012;29(4):388–397.
   PubMed Web of Science ®Google Scholar
• Freitas C, Müller RH. Spray-drying of solid lipid nanoparticles (SLNTM). Eur J Pharm Biopharm. 1998;46(2):145–151.
   PubMed Web of Science ®Google Scholar
• Mehnert W. Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–196.
   PubMed Web of Science ®Google Scholar
• Kanojia G, Have R RT, Soema PC, et al. Developments in the formulation and delivery of spray dried vaccines. Hum Vaccines Immunother. 2017;13(10):2364–2378.
   PubMed Web of Science ®Google Scholar
• Gaspar DP, Serra C, Lino PR, et al. Microencapsulated SLN: an innovative strategy for pulmonary protein delivery. Int J Pharm. 2017;516(1–2):231–246.
   PubMedGoogle Scholar
• Wang T, Ma X, Lei Y, et al. Solid lipid nanoparticles coated with cross-linked polymeric double layer for oral delivery of curcumin. Colloids Surf B Biointerfaces. 2016;148:1–11.
   PubMed Web of Science ®Google Scholar
• Wang T, Hu Q, Zhou M, et al. Preparation of ultra-fine powders from polysaccharide-coated solid lipid nanoparticles and nanostructured lipid carriers by innovative nano spray drying technology. Int J Pharm. 2016;511:219–222.
   PubMedGoogle Scholar
• Sithole MN, Choonara YE, du Toit LC, et al. Development of a novel polymeric nanocomposite complex for drugs with low bioavailability. AAPS PharmSciTech. 2018;19:303–314.
   PubMed Web of Science ®Google Scholar
• Lokras C, Cano-Garcia A, Wadhwa G, et al. Identification of factors of importance for spray drying of small interfering RNA-loaded lipidoid-polymer hybrid nanoparticles for inhalation. Pharm Res. 2019;36:142.
   PubMed Web of Science ®Google Scholar
• Patel AK, Kaczmarek JC, Bose S, et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv Mater. 2019;31:e1805116.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Man R, Liao Q, et al. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102–115.
   PubMed Web of Science ®Google Scholar
• Globenewswire. 2022. https://www.globenewswire.com/en/news-release/2022/07/19/2481569/0/en/The-global-microfluidic-devices-market-is-predicted-to-reach-US-34-5-Billion-by-2028.html. [Accessed 2022 August 1]
   Google Scholar
• Shepherd SJ, Warzecha CC, Yadavali S, et al. Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device. Nano Lett. 2021;21:5671–5680.
   PubMed Web of Science ®Google Scholar
• Carvalho BG, Ceccato BT, Michelon M, et al. Advanced microfluidic technologies for lipid nano-microsystems from synthesis to biological application. Pharmaceutics. 2022;14:141.
   PubMed Web of Science ®Google Scholar
• Pagels RF, Edelstein J, Tang C, et al. Controlling and predicting nanoparticle formation by block copolymer directed rapid precipitations. Nano Lett. 2018;18:1139–1144.
   PubMed Web of Science ®Google Scholar
• Johnson BK, Prud’homme RK. Chemical processing and micromixing in confined impinging jets. AIChE J. 2003;49:2264–2282.
   Web of Science ®Google Scholar
• Johnson BK, Prud’homme RK. Mechanism for rapid self-assembly of block copolymer nanoparticles. Phys Rev Lett. 2003;91:1–4.
   Web of Science ®Google Scholar
• Lim JM, Swami A, Gilson LM, et al. Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano. 2014;8:6056–6065.
   PubMed Web of Science ®Google Scholar
• Chemtrix. 2022. https://chemtrix.com/news/pfizer-showcase-industrial-scale-continuous-manufacturing [Accessed 2022 August 1]
   Google Scholar